SGSarah Guégan

Sarah Guégan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sarah Guégan has a total of 345 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • ADAR1 loss-of-function variants altering RNA editing define a new interferon-dependent psoriasis subtype

    by Florence Assan, Margot Tragin, Sahiti Marella, Joanna Lipecka, Kévin Roger, Mohammed Zarhrate, Vincent Bondet, Vincent Nguyen, Fadela Akroun, Patrick Nitschké, et al.

    Recent evidence implicates altered RNA editing and dysregulated type I IFN signaling in immune-mediated diseases, including psoriasis, although the underlying genetic mechanisms remain poorly defined. We investigated four unrelated multiplex families with early-onset plaque psoriasis, with or without psoriatic arthritis, segregating as a monogenic trait and characterized by a strong IFN signature in skin and blood. Whole-exome sequencing identified four rare heterozygous loss-of-function mutations in ADAR1 cosegregating with disease and elevated IFN-stimulated gene expression. Six additional rare variants were detected in an independent cohort of 125 psoriasis patients. Single-cell transcriptomics identified keratinocytes and melanocytes as major IFN sources. Functional studies showed that ADAR1 knockdown or expression of ADAR1G1119R and ADAR1P3A alleles pathogenic variants reduced adenosine-to-inosine RNA editing and increased IFN-stimulated genes and inflammatory cytokines, effects reversed by upadacitinib and deucravacitinib. These findings define a novel IFN-dependent psoriasis subtype caused by inborn defects of ADAR1-mediated RNA editing, with direct implications for precision medicine in psoriatic disease.


  • Open Access

    Spatially resolved diversity in molecular states underlies congenital melanocytic nevi and associated tumors

    by Daniel Aldea, Sarah Guégan, Israa Fakih, Mathias Moreno, Arnaud de la Fouchardière, Daniel Pissaloux, Franck Tirode, Joan Anton Puig-Butillé, José-Luis Villanueva-Cañas, Teresa Torres-Moral, et al.

    The congenital melanocytic nevus (CMN) is a developmental skin disorder characterized by prenatal melanocyte overgrowth, exhibiting heterogeneity in surface size, depth, and clinical behavior. Large/giant CMN carry an elevated, anticipatory melanoma risk relative to more common, small CMN. However, deeper insights into melanocytic states, genomic and epigenomic alterations, and microenvironmental cues governing disease progression are needed to predict lesions disposed to transformation. Although large/giant CMN melanocyte heterogeneity was recently established, spatial organization of these states and their niche interactions are unknown. Using advanced spatial and single-cell transcriptomics and bulk methylomics, we characterized ten CMN, seven CMN-associated proliferative nodules and three clinically diagnosed melanomas arising in CMN from children, integrating data from healthy skin references to contextualize melanocyte states in situ . CMN-specific melanocytic states, distinct in differentiation and proliferation, were spatially stratified, with immature melanocytes in deep dermis and more differentiated melanocytes approaching the epidermis. We then constructed a robust atlas of CMN cellular states by integrating single-cell transcriptomic data from five new large/giant CMN with published datasets, using it to deconvolute the spatial information. Cell–cell communication inference uncovered enhanced signaling (e.g. pleiotrophin, IGF1, periostin, semaphorin pathways) between CMN melanocytes, fibroblasts, and hair follicle–associated cells. Analysis of CMN-derived tumors, including longitudinal cases with ≥2 samples, revealed divergent spatial melanocytic transcription distinguishing immune-enriched lesions from tumors with oncogenic/pro-invasive signatures. Collectively, these findings establish a spatially resolved framework linking melanocyte heterogeneity, signaling, and genomic instability in CMN, providing mechanistic insights to refine risk stratification and prognosis for CMN-associated tumors.

  • Genetic landscape of non‐ UV ‐induced cutaneous squamous cell carcinomas

    by Carmen Al Youssef, Mansour Alkobtawi, Rémi Safi, Johan Chanal, Pierre Sohier, Stéphanie Leclerc‐Mercier, Ouidad Zehou, Nicolas Ortonne, Philippe Moguelet, Patricia Senet, et al.

    Cutaneous squamous cell carcinoma (cSCC) is the second most common skin cancer and is most often caused by cumulative UV exposure. However, cSCC may also arise independently of UV exposure, on sites of sustained skin damage like chronic ulcers, scars, Recessive Dystrophic Epidermolysis Bullosa (RDEB), and inflammatory skin diseases such as hidradenitis suppurativa (HS). Little is known about non‐UV‐induced skin carcinomas. We aimed to describe the clinical, pathological, and genetic features, of non‐UV‐induced cSCC. We collected clinical and pathologic data corresponding to 31 patients with non‐UV‐induced cSCC, including 5 cSCC on HS, 4 on chronic leg ulcers and 8 on RDEB. DNA was extracted from FFPE samples and analysed using a NGS assay targeting 523 cancer genes. A comparison was performed with published genetic data obtained in non‐UV‐induced and UV‐induced cSCC. We found that the Tumour Mutational Burden (TMB) of non‐UV‐induced cSCC was 6‐times lower than the published TMB of UV‐induced cSCC. The predominant mutational signature was a clock‐wise signature. By comparing the frequency of driver mutations, we found TP53 and NOTCH1 to be significantly less frequently mutated than in UV‐mutated cSCC. Interestingly, KMT2B (a histone methyl transferase) was mutated in 11/31 non‐UV‐induced cSCC and this proportion was significantly higher than in UV‐mutated cSCC. These mutations were high impact loss‐of‐function mutations. We found that knocking down KMT2B expression using siRNA did not affect cell proliferation of SCC‐13 and A‐431 cell lines, however, it significantly increased cell migration in vitro . Taken together, this study provides a comprehensive description of non‐UV‐induced cSCC and identifies that KMT2B is mutated and involved in non‐UV‐induced cSCC carcinogenesis. © 2025 The Pathological Society of Great Britain and Ireland.

  • Open Access

    Cemiplimab versus historical systemic treatments for locally advanced or metastatic cutaneous squamous cell carcinomas: Results from the French study TOSCA

    by Caroline Robert, Emilie Gerard, Emilie Lanoy, Gaëlle Quéreux, P. Bernard, Manuelle-Anne Viguier, Florent Grange, N. Meyer, M. Dinulescu, Delphine Legoupil, et al.

    Background Cemiplimab an anti-programmed cell death receptor-1 antibody, was approved by the FDA and EMA for patients with locally advanced cutaneous squamous cell carcinoma (laCSCC) ineligible for curative surgery/radiotherapy or with metastatic (m) CSCC. TOSCA study evaluated the real-world effectiveness and safety of cemiplimab compared to historical systemic therapies (HSTs). Methods TOSCA (NCT05302297) was a large French retrospective, multicenter study comparing patient with la/mCSCC treated with cemiplimab via the early access program (EAP, 2018–2019) or HST (2013–2018). The primary endpoint was overall survival (OS); secondary endpoints were progression-free survival (PFS), duration of response (DoR), overall response rate (ORR), and safety. Effectiveness analysis using inverse probability weighting included a trial-like cohort of only immunocompetent patients meeting the EAP criteria to emulate a randomized clinical trial; safety analysis included all real-life patients. Findings The study included 280 real-life patients (cemiplimab: n=147; HST: n=133). The primary effectiveness analysis included a trial-like cohort (cemiplimab: n=129; HST: n=70; median age: 81 and 78 years, respectively). Median follow-up was 20 and 10 months in the cemiplimab and HST arms, respectively; median OS was 21.2 and 9.8 months, respectively (HR 95% CI: 0.57 [0.45–0.73]; P<0.0001); median PFS was 13.7 and 5.3 months, respectively (HR [95% CI]: 0.57 [0.43–0.76]; P=0.0001). Adverse drug reactions occurred in 27% of cemiplimab patients and 33% of HST patients. . Interpretation TOSCA demonstrated better survival and response outcomes for cemiplimab versus HST in la/mCSCC; emphasizing, the importance of rigorous retrospective studies in the absence of standard comparative trials. Funding Sanofi.

  • β-Lactam allergy management: A practical approach for clinical decision-making

    by Florian Blanchard, Sarah Guegan, Laurent Chouchana, Etienne Canouï, Caroline Charlier

  • Abdominal metastases from Merkel cell carcinoma: Prevalence and presentation on CT examination in 111 patients

    by Raphael Girard, Manel Djelouah, Maxime Barat, Paul Fornès, Sarah Guégan, Nicolas Dupin, Philippe Soyer, Christine Hoeffel


  • Réactions cutanées rares aux vaccins contre la COVID-19 : série de cas monocentrique et revue de la littérature

    by Elissa Annabi, Nicolas Dupin, Bethsabée Garel, Nathalie Franck, Selim Aractingi, Pierre Sohier, Sarah Guegan, Bénédicte Oulès

  • Immune checkpoint inhibitor-induced hypophysitis

    by David Dudoignon, Sarah Guégan, Maxime Barat


  • Open Access

    Rare cutaneous adverse effects of COVID‐19 vaccines: a case series and review of the literature

    by E. Annabi, N. Dupin, P. Sohier, B. Garel, N. Franck, S. Aractingi, S. Guégan, B. Oulès